About the Event
For the past 36 years, Dr. John Abeles has either been investing in or founding pharmaceutical and
medical companies. During that time, he’s learned a thing or two.
Join us for a fireside chat as Dr. Abeles and Bryologyx CEO, Thomas Loarie, share their best practices in
healthcare investing and talk about their latest endeavor, Bryologyx, Inc.
BryoLogyx is developing a platform of antigen stimulating drugs that make tumors more “visible” to
therapeutics by increasing the expression of cell surface antigens. This makes current therapies more
effective.
Join our webinar to hear from these experienced leaders and why they consider Bryologyx to be a
crucial platform for the future of Immunology.